Market Cap: $58.01B
TL
Takeda Pharmaceutical Company Limited
TAK
NYSE (New York Stock Exchange)USD
Market Cap: $58.01B
Takeda Pharmaceutical Company (Ticker: TAK) continues to demonstrate robust financial health in the competitive pharmaceutical market, despite facing challenges from generic competition that affects i…
Eli Lilly's Strategic Expansion in Neuroscience: Implications for the Competitive Landscape Eli Lilly and Company takes a significant step in the neuroscience space with its recent announcement to acq…
Takeda Pharmaceutical Company Targets Innovations in Mental Health Treatments In a landscape where mental health disorders impact over 970 million individuals globally, Takeda Pharmaceutical Company r…
Innovative Serotonergic Therapies on the Rise in Mental Health Treatment Helus Pharma is making significant strides in the booming mental health therapeutics market, which is set to surpass $40 billio…
Takeda’s late‑stage win for Entyvio reshapes its gastroenterology strategy Takeda Pharmaceutical is presenting positive Phase 3 results for its biologic Entyvio in a late‑stage clinical study, a devel…
Takeda’s late‑stage win reported for Entyvio Takeda Pharmaceutical Co Ltd is reporting positive Phase 3 results for Entyvio in a late‑stage clinical study, a development that strengthens the evidence…
Subcutaneous push reshapes Takeda’s biologics strategy Takeda and other large drugmakers are reassessing delivery strategies as the industry shifts toward subcutaneous administration of antibody thera…
Takeda Weighs the Shift to Subcutaneous Delivery Partnerships Takeda Pharmaceutical Company faces a strategic decision as the pharmaceutical industry increasingly adopts enzyme‑mediated subcutaneous d…
Serotonergic agonists reshape big‑pharma CNS strategy Takeda Pharmaceutical and other large drugmakers are closely watching the rise of novel serotonergic agonists (NSAs) as a new class of central ner…
Takeda narrows focus on serotonergic agonists to refresh CNS pipeline Takeda Pharmaceutical Company is among a group of major drugmakers that are actively pursuing novel serotonergic agonists (NSAs) a…
Takeda Pharmaceutical Company Joins BaseLaunch: A Strategic Move to Boost Biotech Innovation Takeda Pharmaceutical Company strengthens its commitment to biotechnology innovation by officially joining…
Takeda Pharmaceutical Company Strengthens Biotech Ties Through BaseLaunch Partnership Takeda Pharmaceutical Company has made a significant move in the biotech landscape by officially joining BaseLaunc…
Innovative Collaboration: Takeda and Innovent Biologics Team Up in Immuno-Oncology In a significant advancement in cancer treatment, Takeda Pharmaceutical Company has successfully closed a strategic c…
Takeda and Innovent Forge Strategic Alliance to Advance Cancer Therapies In a significant development within the biopharmaceutical sector, Takeda Pharmaceutical Company has finalized a strategic colla…
Adzynma's Safety Concerns Prompt FDA Vigilance The recent reports from the U.S. Food and Drug Administration (FDA) regarding Takeda Pharmaceutical Company's recombinant ADAMTS13 product, Adzynma, rais…
Takeda Pharmaceutical: Driving Innovation Amid Market Challenges Takeda Pharmaceutical Company stands at the forefront of biotechnology and pharmaceuticals, focusing on innovative treatments that addr…
Takeda Pharmaceutical's Focus on Strategic Growth Amid Industry Challenges Takeda Pharmaceutical Company continues to navigate the complexities of the global healthcare landscape, with a keen emphasis…
Takeda Partners with TetraScience to Revolutionize Biopharmaceutical R&D On October 24, 2025, Takeda Pharmaceutical Company joins forces with TetraScience, a leading scientific data and AI company, as…
Takeda Pharmaceutical Partners with TetraScience to Drive Innovation in Drug Development In a significant collaboration, Takeda Pharmaceutical Company teams up with TetraScience, a leader in scientifi…
Takeda and Innovent Forge Strategic Alliance to Advance Immuno-Oncology Therapies In a significant development within the biopharmaceutical sector, Takeda Pharmaceutical Company and Innovent Biologics…
### Takeda Pharmaceutical Company Strengthens Position in Cancer Treatment Through Strategic Collaboration Takeda Pharmaceutical Company embarks on a transformative partnership with Innovent Biologics…
Nabla Bio and Takeda Forge Strategic Partnership to Enhance Drug Discovery In a significant development within the biotechnology sector, Nabla Bio has entered into a multi-year research collaboration…
Takeda Pharmaceutical Faces Competitive Landscape Amid Industry Consolidation In light of ongoing negotiations between Johnson & Johnson and Protagonist Therapeutics, Takeda Pharmaceutical Company fin…
TAK Broadband Expands Southern California Presence with GSI Acquisition In a strategic move to bolster its operations in California, TAK Broadband has announced the acquisition of Gulbranson Services,…
TAK Broadband Strengthens Market Position with Strategic Acquisition TAK Broadband, a national provider of fiber and broadband network services, announces its acquisition of Gulbranson Services, Inc.…